Antibacterial antibodies (Sorrento Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAntibacterial antibodies (Sorrento Therapeutics)
Drug Alias NameSTI 001 program - SorrentoAnti-MRSA antibodies - Sorrento TherapeuticsAnti-API2 mAbsAnti-API1 mAbAnti-AIP mAbs +[7] 
ClassificationBiologics
Mechanisms of ActionImmunostimulantsPeptides inhibitors
TargetsPeptides
Therapy Area/IndicationsStaphylococcal InfectionsPseudomonas Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe Ohio State UniversitySorrento Therapeutics IncUniversity Of Montana
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Ohio State UniversitySorrento Therapeutics IncUniversity Of Montana
Active IndicationsN/A
Inactive IndicationsStaphylococcal InfectionsPseudomonas Infections

Other Information

ATC CodeN/A
Related LinksN/A